The unique association of malignant histiocytosis and a primary gonadal germ cell tumorMARGOLIN, K; TRAWEEK, T.Medical and pediatric oncology. 1992, Vol 20, Num 2, pp 162-164, issn 0098-1532Article

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanomaLEE, P; WANG, F; MARTY, V et al.Journal of clinical oncology. 2001, Vol 19, Num 18, pp 3836-3847, issn 0732-183XArticle

Mitomycin C and menadione for the treatment of lung cancer : a phase II trialTETEF, M; MARGOLIN, K; AHN, C et al.Investigational new drugs. 1995, Vol 13, Num 2, pp 157-162, issn 0167-6997Article

Fractionated total-body irradiation and high-dose etoposide as a preoaratory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phaseSNYDER, D. S; NEGRIN, R. S; SOMLO, G et al.Blood. 1994, Vol 84, Num 5, pp 1672-1679, issn 0006-4971Article

Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-upMORGAN, R. J; BRALY, P; RASCHKO, J et al.Gynecologic oncology (Print). 1999, Vol 75, Num 3, pp 419-426, issn 0090-8258Article

Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapySOMLO, G; SNIECINSKI, I; MARGOLIN, K et al.Blood. 1999, Vol 93, Num 9, pp 2798-2806, issn 0006-4971Article

Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell supportMARGOLIN, K; DOROSHOW, J. J; AHN, C et al.Journal of clinical oncology. 1996, Vol 14, Num 10, pp 2631-2637, issn 0732-183XArticle

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma : Analysis of 270 patients treated between 1985 and 1993ATKINS, M. B; LOTZE, M. T; PARADISE, C et al.Journal of clinical oncology. 1999, Vol 17, Num 7, pp 2105-2116, issn 0732-183XArticle

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer : Prognostic indicators of progression-free and overall survivalSOMLO, G; DOROSHOW, J. H; RASCHKO, J et al.Journal of clinical oncology. 1997, Vol 15, Num 8, pp 2882-2893, issn 0732-183XArticle

Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma : International Index high and high-intermediate risk groupNADEMANEE, A; MOLINA, A; SPIELBERGER, R et al.Blood. 1997, Vol 90, Num 10, pp 3844-3852, issn 0006-4971Article

Modulation of 5-fluorouracil with high-dose leucovorin calcium : activity in ovarian cancer and correlation with CA-125 levelsMORGAN, R. J; SPEYER, J; AHN, C et al.Gynecologic oncology (Print). 1995, Vol 58, Num 1, pp 79-85, issn 0090-8258Article

Phase I trial of carboplatin and infusional cyclosporine in advanced malignancyMORGAN, R. J; MARGOLIN, K; RASCHKO, J et al.Journal of clinical oncology. 1995, Vol 13, Num 9, pp 2238-2246, issn 0732-183XArticle

Thalidomide as salvage therapy for chronic graft-versus-host diseasePARKER, P. M; CHAO, N; KASHYAP, A et al.Blood. 1995, Vol 86, Num 9, pp 3604-3609, issn 0006-4971Article

High-titer, high-thermal-amplitude cold autoagglutinin not associated with hemolytic anemiaSNIECINSKI, I; MARGOLIN, K; SHULMAN, I et al.Vox sanguinis (Basel. 1956). 1988, Vol 55, Num 1, pp 26-29, issn 0042-9007Article

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in manTEXTOR, S. C; MARGOLIN, K; BLAYNEY, D et al.The American journal of medicine. 1987, Vol 83, Num 6, pp 1055-1061, issn 0002-9343Article

Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancerSOMLO, G; SIMPSON, J. F; KOGUT, N et al.British journal of cancer. 2002, Vol 87, Num 3, pp 281-288, issn 0007-0920, 8 p.Article

Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma : A phase II trialTETEF, M; LEONG, L; DOROSHOW, J. H et al.Cancer investigation. 1999, Vol 17, Num 2, pp 114-117, issn 0735-7907Article

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remissionSNYDER, D. S; NADEMANEE, A. P; FUNG, H et al.Leukemia. 1999, Vol 13, Num 12, pp 2053-2058, issn 0887-6924Article

Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanomaMARGOLIN, K; ATKINS, M; CAMPBELL, E et al.Clinical cancer research. 1997, Vol 3, Num 4, pp 565-572, issn 1078-0432Article

High-dose infusional doxorubicin and cyclophosphamide : A feasibility study of tandem high-dose chemotherapy cycles without stem cell supportMORGAN, R. J; DOROSHOW, J. H; MARGOLIN, K et al.Clinical cancer research. 1997, Vol 3, Num 12, pp 2337-2345, issn 1078-0432, 1Article

Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomachSOMLO, G; DOROSHOW, J; AKMAN, S et al.Investigational new drugs. 1991, Vol 9, Num 1, pp 83-85, issn 0167-6997, 3 p.Article

A phase II study of high-dose continous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanomaDUTCHER, J. P; GAYNOR, E. R; MARGOLIN, K et al.Journal of clinical oncology. 1991, Vol 9, Num 4, pp 641-648, issn 0732-183XArticle

Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancerMARGOLIN, K; AKMAN, S; CARR, B et al.American journal of clinical oncology. 1988, Vol 11, Num 4, pp 499-501, issn 0277-3732Article

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working GroupMARGOLIN, K; ATKINS, M. B; DUTCHER, J. P et al.Journal of cancer research and clinical oncology. 2002, Vol 128, Num 4, pp 214-218, issn 0171-5216Article

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II Cytokine Working Group trialsFLAHERTY, L. E; ATKINS, M; SOROKIN, P et al.Journal of clinical oncology. 2001, Vol 19, Num 13, pp 3194-3202, issn 0732-183XArticle